Literature DB >> 9694752

Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study.

R Boer1, H de Koning, A Threlfall, P Warmerdam, A Street, E Friedman, C Woodman.   

Abstract

OBJECTIVE: To compare the cost effectiveness of two possible modifications to the current UK screening programme: shortening the screening interval from three to two years and extending the age of invitation to a final screen from 64 to 69.
DESIGN: Computer simulation model which first simulates life histories for women in the absence of a screening programme for breast cancer and then assesses how these life histories would be changed by introducing different screening policies. The model was informed by screening and cost data from the NHS breast screening programme.
SETTING: North West region of England. MAIN OUTCOME MEASURES: Numbers of deaths prevented, life years gained, and costs.
RESULTS: Compared with the current breast screening programme both modifications would increase the number of deaths prevented and the number of life years saved. The current screening policy costs 2522 pounds per life year gained; extending the age range of the programme would cost 2612 pounds and shortening the interval 2709 pounds per life year gained. The marginal cost per life year gained of extending the age range of the screening programme is 2990 pounds and of shortening the screening interval is 3545 pounds.
CONCLUSIONS: If the budget for the NHS breast screening programme were to allow for two more invitations per woman, substantial mortality reductions would follow from extending the age range screened or reducing the screening interval. The difference between the two policies is so small that either could be chosen.

Entities:  

Mesh:

Year:  1998        PMID: 9694752      PMCID: PMC28630          DOI: 10.1136/bmj.317.7155.376

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  8 in total

1.  A model for breast cancer screening.

Authors:  G J van Oortmarssen; J D Habbema; P J van der Maas; H J de Koning; H J Collette; A L Verbeek; A T Geerts; K T Lubbe
Journal:  Cancer       Date:  1990-10-01       Impact factor: 6.860

2.  How cost-effective is breast cancer screening in different EC countries?

Authors:  B M van Ineveld; G J van Oortmarssen; H J de Koning; R Boer; P J van der Maas
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 3.  Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature.

Authors:  M L Brown; L Fintor
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors.

Authors:  H J de Koning; B M van Ineveld; G J van Oortmarssen; J C de Haes; H J Collette; J H Hendriks; P J van der Maas
Journal:  Int J Cancer       Date:  1991-10-21       Impact factor: 7.396

5.  National Health Service breast screening programme results for 1991-2.

Authors:  J Chamberlain; S M Moss; A E Kirkpatrick; M Michell; L Johns
Journal:  BMJ       Date:  1993-08-07

6.  Prediction of the effects and costs of breast-cancer screening in Germany.

Authors:  P M Beemsterboer; H J de Koning; P G Warmerdam; R Boer; E Swart; M L Dierks; B P Robra
Journal:  Int J Cancer       Date:  1994-09-01       Impact factor: 7.396

7.  Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials.

Authors:  H J de Koning; R Boer; P G Warmerdam; P M Beemsterboer; P J van der Maas
Journal:  J Natl Cancer Inst       Date:  1995-08-16       Impact factor: 13.506

8.  A model-based prediction of the impact on reduction in mortality by a breast cancer screening programme in the city of Florence, Italy.

Authors:  E Paci; R Boer; M Zappa; H J de Koning; G J van Oortmarssen; E Crocetti; D Giorgi; M Rosselli del Turco; J D Habbema
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

  8 in total
  15 in total

1.  Impact of UK policy initiatives on use of medicines to aid smoking cessation.

Authors:  R West; M E DiMarino; J Gitchell; A McNeill
Journal:  Tob Control       Date:  2005-06       Impact factor: 7.552

Review 2.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Extending the benefits of breast cancer screening. Still hard to know how large the benefits will really be.

Authors:  U Werneke; K McPherson
Journal:  BMJ       Date:  1998-08-08

4.  NHS breast screening programme. Both extended age range and reduced screening interval are needed.

Authors:  H Goodare; M King
Journal:  BMJ       Date:  1999-02-06

5.  The financial cost of preventive and curative programs for breast cancer: a case study of women in Shiraz-Iran.

Authors:  Nahid Hatam; Vahid Keshtkar; Asiyeh Salehi; Hamidreza Rafei
Journal:  Int J Health Policy Manag       Date:  2014-05-08

6.  Tumour doubling times and the length bias in breast cancer screening programmes.

Authors:  Israel T Vieira; Valter de Senna; Paul R Harper; Arjan K Shahani
Journal:  Health Care Manag Sci       Date:  2011-03-29

7.  Universal HIV screening of pregnant women in England: cost effectiveness analysis.

Authors:  M J Postma; E J Beck; S Mandalia; L Sherr; M D Walters; H Houweling; J C Jager
Journal:  BMJ       Date:  1999-06-19

8.  Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines.

Authors:  Charlotte Hsieh Ahern; Yu Shen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-03       Impact factor: 4.254

9.  Cost effectiveness of breast cancer screening using mammography; a systematic review.

Authors:  Arash Rashidian; Eshagh Barfar; Hamed Hosseini; Shirin Nosratnejad; Esmat Barooti
Journal:  Iran J Public Health       Date:  2013-04-01       Impact factor: 1.429

10.  Cost effectiveness of the NHS breast screening programme: life table model.

Authors:  Paul D P Pharoah; Bernadette Sewell; Deborah Fitzsimmons; Hayley S Bennett; Nora Pashayan
Journal:  BMJ       Date:  2013-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.